The results described above demonstrate that the delineation of breast cancer subtypes can be correlated to diverging paths with regards to control samples, where basal-like and HER2-enriched subtypes differ from luminal A in several probes with a relative under-expression in one and an over-expression in the other group, when compared to controls. The gene discussed is ERBB2; the disease is breast cancer.